Clinical trial
A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)
NCT01381692 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 20, 2011
- Completion date
- September 1, 2021
- Enrollment
- 9 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, recurrent waldenstrom macroglobulinemia, refractory follicular lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma